SCHEMBL3297166

SCHEMBL3297166

CCCCCCCCOc1ccc(C=NO)c(O)c1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR5A1 Q13285 1/20 0.55
LTA4H P09960 2/20 0.49
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
CNR2 P34972 2/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
MAPT P10636 2/20 0.47
GAA P10253 2/20 0.47
TP53 P04637 2/20 0.47
LMNA P02545 1/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
RAF1 P04049 1/20 0.45
MAPK1 P28482 1/20 0.45
TSHR P16473 2/20 0.43
TLR4 O00206 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3297164 1.00 NR5A1 (0.55) NR5A1LTA4HMEN1KMT2ACNR2
SCHEMBL28212996 1.00 NR5A1 (0.55) NR5A1LTA4HMEN1KMT2ACNR2
SCHEMBL28212995 1.00 NR5A1 (0.55) NR5A1LTA4HMEN1KMT2ACNR2
SCHEMBL7561057 0.89 NR5A1 (0.51) NR5A1LTA4HMEN1KMT2ACNR2
SCHEMBL7561060 0.89 NR5A1 (0.51) NR5A1LTA4HMEN1KMT2ACNR2
SCHEMBL17743570 0.87 NR5A1 (0.54) NR5A1LTA4HMEN1KMT2ACNR2
SCHEMBL17743572 0.87 NR5A1 (0.54) NR5A1LTA4HMEN1KMT2ACNR2
SCHEMBL31111418 0.86 HPGD (0.49) NR5A1MEN1KMT2ANPC1RAB9A
SCHEMBL318148 0.86 HPGD (0.49) NR5A1MEN1KMT2ANPC1RAB9A
SCHEMBL318149 0.86 HPGD (0.49) NR5A1MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060173058-A1 Kcnq channel modulating compounds and their pharmaceutical use NEUROSEARCH A/S (DK) 2006-08-03 US claimed
EP-1603858-A2 KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE NeuroSearch A/S (DK) 2005-12-14 EP claimed
WO-2004080377-A2 KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE NEUROSEARCH A/S (DK) 2004-09-23 WO claimed
US-7741352-B2 KCNQ channel modulating compounds and their pharmaceutical use NEUROSEARCH A/S (DK) 2010-06-22 US disclosed
US-7741352-B2 KCNQ channel modulating compounds and their pharmaceutical use NEUROSEARCH A/S (DK) 2010-06-22 US disclosed
US-20060173058-A1 Kcnq channel modulating compounds and their pharmaceutical use NEUROSEARCH A/S (DK) 2006-08-03 US disclosed
EP-1603858-A2 KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE NeuroSearch A/S (DK) 2005-12-14 EP disclosed
WO-2004080377-A2 KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE NEUROSEARCH A/S (DK) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173058-A1 Kcnq channel modulating compounds and their pharmaceutical use KCNQ1, KCNQ2, KCNQ5 NR5A1 2668/4885LTA4H 2177/4885MEN1 1783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.